Activation of the kynurenine pathway is one of the described mechanisms by which inflammation can induce depression. It involves multiple pathways including interference with the bioavailability of tryptophan central to the synthesis of the neurotransmitter serotonin.
Introduction
Major depressive disorder (MDD) and bipolar disorder (BD) are leading causes of mental disorders worldwide (Whiteford et al., 2013) . They are a major public health concern due to their chronicity, risk of suicide and high co-morbidity with other disabling diseases such as diabetes and cardiovascular diseases (Angst et al., 2013; Barth et al., 2004; Fornaro et al., 2017; Greenberg et al., 2015; Hesdorffer et al., 2000; Knol et al., 2006; Simon, 2003) . The underlying pathophysiology of these disorders is complex, possibly involving multiple biological systems including immune, endocrine, and metabolic processes impacting the functional and structural aspects of the brain. Understanding this pathophysiology is critical for the development of new treatment and effective relapse prevention strategies.
A consistent body of evidence from both preclinical and clinical studies shows that inflammation in both periphery and the central nervous system plays a role in the pathophysiology of mood disorders. Elevated peripheral pro-inflammatory markers have been associated with depression and bipolar disorders (Miller et al., 2009; Strawbridge et al., 2015) . Further evidence originates from the clinical observation that one-third of patients treated for cancer or hepatitis C with the proinflammatory cytokine interferon-alpha (IFNα) develop MDD (Widner et al., 2000) whereas anti-inflammatory agents such as cyclooxygenase-2 (COX-2) inhibitors and N-acetyl cysteine could contribute to alleviating depressive symptoms (Müller, 2010) . In addition, the prevalence of MDD is higher in patients with chronic medical conditions such as rheumatoid arthritis and type 2 diabetes which are often characterized by low-grade chronic inflammation (Katon et al., 2010) .
Communication between the immune system and the brain takes place through multiple pathways, including neural afferents and circulating immune mediators which activate brain endothelial and innate immune cells (perivascular and meningeal macrophages, microglia) (Dantzer et al., 2008) . Activated microglia release pro-inflammatory cytokines such as IL-1, IL-6, TNF, and prostaglandins (Perry et al., 2010) . Dysregulation of this reciprocal interaction between the nervous and immune systems may lead to neuronal damage or https://doi.org/10.1016/j.neubiorev.2018.05.031 Received 29 November 2017; Received in revised form 28 May 2018; Accepted 29 May 2018 neurodegeneration (Miller et al., 2009) .
Serotonin is biochemically derived from tryptophan (TRP). Decreased brain serotoninergic neurotransmission forms the basis of the serotonin hypothesis of depression (Coppen, 1968) . Activation of the kynurenine pathway (KP) is one of the potential mechanisms by which inflammation can induce depression by interfering with the metabolism of TRP (Dantzer et al., 2011; Oxenkrug, 2010) . Two major enzymatic pathways metabolize TRP. One pathway utilizes the liver enzyme tryptophan 2, 3 dioxygenase (TDO2) of which the activity is regulated by glucocorticoids. The other pathway is regulated by the ubiquitous indoleamine 2, 3 dioxygenase (IDO1) enzyme. IDO1 is activated by proinflammatory cytokines especially interferon gamma (IFNγ). Downstream of IDO1, two separate metabolic pathways transform kynurenine (KYN), the main metabolite of TRP, to the neuroprotective kynurenic acid (KYNA) in astrocytes or the neurotoxic 3-hydroxykynurenine (3-HK) and quinolinic acid (QUIN) in microglia (Müller and Schwarz, 2008; Schwarcz et al., 2012) . This latter pathway is regulated by activation of microglial kynurenine mono-oxygenase (KMO). KYN/TRP ratio provides a measure of peripheral tryptophan breakdown and is used as an index of IDO1 activity when observed with other immune activation markers such as neopterin (Dantzer et al., 2011) .
Current pathogenic models suggest that elevated pro-inflammatory cytokines activate IDO1 and KMO resulting in increased susceptibility to MDD (Campbell et al., 2014) by switching the kynurenine metabolites balance towards neurotoxicity (Müller and Schwarz, 2008; Myint and Kim, 2003) . Moreover, preclinical studies have demonstrated that inflammation-induced depression is mediated by increased brain levels of QUIN activating NMDA receptors (Walker et al., 2013) . This is in agreement with the therapeutic role of ketamine in the treatment of MDD and the central role played by astrocytes and microglia in glutamine/glutamate dysregulation , potentially enhancing neurotoxicity of quinolinic acid (Dantzer and Walker, 2014) . Thus, KYNA/QA ratio is proposed as putative neuroprotection index in that decreases in the ratio may contribute to inflammation-induced pathology (Savitz et al., 2015a, b) .
Results from prospective cohort studies in which patients with cancer or hepatitis C virus infection are administered IFN-alpha and mood symptoms are assessed longitudinally together with KP metabolites reveal consistent increases in plasma KYN metabolites associated with symptoms of depression and support the 'inflammatory hypothesis' for depression pathogenesis (Baranyi et al., 2015; Bonaccorso et al., 2002; Capuron et al., 2003) . Activation of KP is associated with decreased TRP, increased KYN, increased KYN/TRP ratio and possibly decrease in the neuroprotective index KYNA/QA ratio. A meta-analysis of studies measuring plasma tryptophan levels in patients with MDD showed reduced plasma TRP levels (Ogawa et al., 2014) (Ogawa et al., 2014) . However, the results from studies measuring peripheral bloodbased KP metabolites in mood disorders are not always consistent, as increases, decreases or no changes in KP metabolites have been reported.
In this review, we examine the relationship between activation of the kynurenine pathway and mood disorders by systematically reviewing the literature and by running a meta-analysis. We specifically included studies that investigated tryptophan and kynurenine metabolites (tryptophan, kynurenine, kynurenic acid, quinolinic acid, ratio of kynurenine to tryptophan) in patients with MDD or BD. We predicted that decreased TRP, increased KYN, increased KYN/TRP ratio and decreased KYNA/QA ratio would be associated with MDD and BD.
Methods

Search strategy
The review process adhered to the principles of the PRISMAStatement ( . We intended to study the relationship between activation of the kynurenine pathway and mood disorders. Eligibility criteria included: 1) English language articles, 2) Studies published in peer-reviewed journals, and 3) Matched case-control studies comparing patients with mood disorders (unipolar and bipolar disorders) with healthy controls measuring the circulating levels of kynurenine pathway metabolites reported as mean and standard deviation. We also considered longitudinal studies which provided a baseline evaluation. As a secondary analysis, we considered the possibility of measuring longitudinal changes in response to pharmacological or psychological treatment.
We excluded studies carried out in physically ill patients with mood symptoms, e.g., HIV or Hepatitis C infected individuals. We developed a protocol to review study eligibility, information sources, and data elements for abstraction (available upon request [tw] . The detailed search strategy is provided as online Appendix A. Study eligibility was assessed following the criteria are shown in the flowchart in Fig. 1 . Two trained reviewers (SS, HS) independently reviewed the unduplicated records retrieved from the search to assess eligibility and resolved uncertainty by consensus (SSa, HS, and DA). Basic demographic information and clinical variables were systematically extracted including all available levels of metabolites.
Quality assessment, data synthesis, and analysis
Study quality assessment and scoring was carried out by using the 'Study Quality Form' from the 'Guide to Community Preventive Services' (Zaza et al., 2000) and varied based on the 'number of limitations' from 'good' (0-1) to 'fair' (2-4) and 'limited' (≥ 5).
Meta-analysis was conducted using STATA 9.0 (Stata Corp, College Station, Texas) supplemented by 'Metan' software downloadable from the Centre for Statistics in Medicine, Oxford, UK as previously described (Arnone et al., 2009 (Arnone et al., , 2012 Lavagnino et al., 2016; Selvaraj et al., 2014) . Standardised mean differences were calculated using Cohen's d statistic. The presence of heterogeneity was tested using the Q-test. Its magnitude was estimated using I 2 , which can be interpreted as the proportion of effect size variance due to heterogeneity (Higgins et al., 2003) . If the Q-test was significant, Galbraith plot served to identify studies contributing to heterogeneity. We explored heterogeneity with meta-regression by using all the available confounders including a year of publication, mean age, the percentage of depressed men, and illness severity for both symptoms of depression and elation whenever possible. Publication bias was examined using the Egger's test (Egger et al., 1997) with a significance level of p < 0.05.
Results
Study selection
The initial database search identified 1865 eligible studies, 56 survived the initial suitability assessment and additional hand search identified 4 more studies each in MDD and BD respectively. Twenty-one were included in the meta-analysis (14 investigating MDD and 7 BD) ( Fig. 1 : Flow diagram). Table 1 and 2 summarizes the details of the studies included in the meta-analysis and the Supplementary Table describes details of the selection process and quality assessment.
MDD in comparison with healthy controls
Fourteen studies were identified and eleven met inclusion criteria (Baranyi et al., 2017; Bradley et al., 2015; Dahl et al., 2015; Krause et al., 2017; Meier et al., 2016; Myint et al., 2013 Myint et al., , 2007b Neupane et al., 2015; Quak et al., 2014; Savitz et al., 2015b; Sorgdrager et al., 2017; Sublette et al., 2011; Umehara et al., 2017; Wood et al., 1978) having excluded the study by Myint et al. (2013) because cases and controls were not fully matched at baseline, Myint et al. (2007b) which enrolled patients with BD, and Neupane et al. (2015) which included participants with alcohol-related disorders. The studies by Meier et al. (2016) and by Savitz et al. (2015b) contained the same participants and Quak et al. (2014) and Sorgdrager et al. (2017) shared study participants and the study with the largest sample size (Quak et al., 2014) (supplementary data were made available by the authors) and (Meier et al., 2016) were included. Nine studies were included in the quantitative meta-analysis are detailed in Table 1 . The majority of the studies included unmedicated patients aside Quak et al. (2014) , Bradley et al. (2015) and Baranyi et al. (Baranyi et al. (2017) ).
a) Circulating levels of kynurenine
Analysis of the nine studies available (Baranyi et al., 2017; Bradley et al., 2015; Dahl et al., 2015; Krause et al., 2017; Meier et al., 2016; Quak et al., 2014; Sublette et al., 2011; Umehara et al., 2017; Wood et al., 1978) showed a significant reduction in kynurenine in MDD vs. healthy controls with an effect size of -0.21 (CI: -0.39, -0.03) (Fig. 2a ). Significant heterogeneity (p = 0.027) was systematically explored with meta-regression analyses. None of the available variables extracted from the studies proved to explain the variance of the effect size (year of publication, mean age, %men, illness severity, number of medicated individuals, all ps > 0.05). There was no evidence of publication bias (p = 0.47).
b) Circulating levels of tryptophan
Six studies were included in this analysis (Bradley et al., 2015; Dahl et al., 2015; Meier et al., 2016; Quak et al., 2014; Sublette et al., 2011; Wood et al., 1978) which showed a non-significant reduction in levels of TRP in patients with MDD. The effect size was -0.20 (CI: -048, 0.07). There was significant heterogeneity (p = 0.001). Meta-regressions indicated that prescribed medication influenced the effect size (Coef: 0.0007, Z = 3.02, p = 0.003) as well as % men (Coef: -0.01, Z=-2.49, p = 0.013), and year of publication (Coef: -0.17, Z=-3.27, p = 0.001), whereas severity trended to significance (Coef: -0.18, Z=-1.94, p = 0.053) and mean age was not significant (p = 0.57). There was no D. Arnone et al. Neuroscience and Biobehavioral Reviews 92 (2018) [477] [478] [479] [480] [481] [482] [483] [484] [485] TRP -Tryptophan; KYN -Kynurenine; K/T ratio -Kynurenine/Tryptophan ratio; KYNA -Kynurenic Acid; QA -Quinolinic acid.
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evidence of publication bias (p = 0.25).
c) Kynurenine/tryptophan ratio
Six studies were included in this analysis (Baranyi et al., 2017; Bradley et al., 2015; Dahl et al., 2015; Meier et al., 2016; Quak et al., 2014; Sublette et al., 2011) and indicated a trend towards an increase in the kynurenine/tryptophan ratio in MDD with an effect size of 0.18 (CI: -0.06, 0.42). This analysis was characterized by high level of heterogeneity (p = 0.006). The presence of publication bias (p = 0.018) indicated that results from these studies are not necessarily generalizable. Exploration of heterogeneity indicated that the effect size correlated with increasing number of medicated patients (coeff: -0.0002, Z=-3.62, p < 0.001), whereas a year of publication, mean age of the depressed group, % of men and severity did not affect the effect size (all Ps > 0.05).
d) Kynurenic acid/quinolinic acid ratio
There were no sufficient studies in MDD to carry out this analysis.
Bipolar disorder in comparison with healthy controls
Seven studies were identified of which five studies were included (Myint et al., 2007a; Platzer et al., 2017; Poletti et al., 2016; Reininghaus et al., 2014; Savitz et al., 2015a) (Table 2) having excluded the post-mortem study by Miller et al. (2008) and the study by Birner et al. overlapping with Platzer et al. (2017) already included in the same analyses. Overlapping data from Reininghaus et al. (2014) and Platzer et al. (2017) were considered in separate subanalyses. All patients were medicated aside the study by Myint and others (Myint et al., 2007a) resulting in very little variance for a meaningful analysis. 
b) Circulating levels of tryptophan
Four studies were included in this analysis (Myint et al., 2007a; Platzer et al., 2017; Poletti et al., 2016; Savitz et al., 2015a) which showed a non-significant tendency to a reduction in levels of TRP in patients with BD. The effect size was -1.15 (CI: -2.43, 0.1). There was evidence of significant heterogeneity (p < 0.001) in the absence of publication bias (p = 0.3). Meta-regressions indicated that the effect size positively correlated with increasing percentage of men (Coeff: 6.93, Z = 3.04, p = 0.002). Year of publication, mean age of the patients, and severity of illness did not affect the effect size (ps > 0.05).
c) Kynurenine/tryptophan ratio
Four studies were included in this analysis (Myint et al., 2007a; Poletti et al., 2016; Reininghaus et al., 2014; Savitz et al., 2015a) which indicated a non-significant tendency to an increased ratio 0.24 (CI: -0.10, 0.59) with significant heterogeneity (P = 0.025) and no evidence of publication bias (p = 0.35). Meta-regressions indicated that the effect size positively correlated with increasing age (Coeff: 0.056, Z = 2.62, p = 0.009). Year of publication, %men, and severity of illness did not affect the effect size (ps > 0.05).
d) Kynurenic acid/quinolinic acid ratio
There were no sufficient studies in BD to carry out this analysis. Fig. 2 . Meta-analysis output (funnel plot) in the unipolar major depression of circulating levels of kynurenine levels.
Longitudinal studies evaluating the effect of therapeutic interventions and clinical outcome on kynurenine pathways
There were only two studies evaluating the effect of pharmacological interventions on kynurenine pathways in patients with MDD (Krause et al., 2012; Wood et al., 1978) , but none in BD meeting our inclusion criteria. Hence it was not possible to conduct meta-analyses. Wood et al. (1978) found that clinical outcome could not be accurately predicted by measurements of plasma kynurenine levels. They also reported that amitriptyline did not significantly increase plasma kynurenine concentration contrary to lithium and mianserin. Krause and others reported that higher kynurenine/tryptophan ratio at baseline predicted remission in reboxetine-treated patients with MDD with or without adjuvant treatment with the cyclooxygenase-2 inhibitor celecoxib. Remitters were also characterized by lower kynurenic acid/ kynurenine and quinolinic acid/kynurenine ratios. Authors proposed that lower downstream kynurenine metabolites formation were likely to be predictive of better outcome (Krause et al., 2012) .
Discussion
In this manuscript, we set out to review the range of kynurenine metabolites variations in MDD/BD in comparison with healthy controls by selecting the most robust evidence available in the literature to generate summary effect sizes. Our results indicate that although kynurenine metabolites show variations in affected individuals, these changes are of a small magnitude and reach significance in the analysis of kynurenine metabolites in unipolar major depression. Based on the data analyzed, alterations of the balance between neuroprotective and neurotoxic kynurenine metabolites could still play a pathogenic role in subgroups of patients with mood disorders. The direction of changes in kynurenine metabolites which indicates a reduction in major depression vs. healthy controls rather than an increase as we anticipated suggests that major depression in chronic inflammatory conditions may etiologically differ from other depressive disorders.
In both MDD and BD the high level of heterogeneity suggests that a number of confounders and clinical variables are likely to contribute to the effect size so that variables such as year of publication, age of participants, sex, and illness severity for both symptoms of depression and mania appear to influence variations in the effect size. Furthermore, in the case of kynurenine/tryptophan ratio in MDD, the presence of publication bias seems to suggest that studies might be of a too small magnitude to detect meaningful differences without incurring into type I/II error. There were differences in design across all the studies reviewed. For example, a large number of studies were observational and presented naturalistic uncontrolled data. Case-control studies, which represent the main source of this review, did not offer any information regarding the temporal and/or directional relationship between mood disorders and kynurenine metabolites variations. The results from the only two prospective cohort studies that were included in the present metaanalysis provided insufficient data to allow conclusive statements about the generalizability of the results.
Other putative factors shown to affect levels of kynurenine metabolites include antidepressants and other treatments like electroconvulsive therapy (Cervenka et al., 2017) . However, the variations in the effect size of reduction of kynurenine levels seen in MDD patients vs. controls was not explained by the antidepressant medication status in our analyses.
Other potential limitations include the effects of weight and obesity, physical activity, use of tobacco and other addictive drugs. TDO and IDO are two major enzymatic pathways that metabolize TRP with the TDO's activity regulated by glucocorticoids and IDO activated by proinflammatory cytokines such as IFNγ. Effect of dietary modifications, body weight, and physical activity can affect tryptophan levels and therefore kynurenine pathway and its metabolites both in patients with mood disorders and in healthy controls (Cervenka et al., 2017; Strasser, 2017) . However, these factors are not controlled in all studies. For example, Reininghaus et al report increased KYN and KYN/TRY ratio levels in overweight bipolar disorder patients. Future studies should take these factors into consideration when evaluating KP pathway in mood disorders.
The question also remains whether peripheral measurements are the optimal approach to evaluate kynurenine metabolites and whether effectively reflect brain concentrations. Raison et al. (2010) is the only study that evaluated the effect of IFN-alpha/ribavirin therapy on both plasma and cerebrospinal fluid (CSF) levels of TRP, KYN and QUIN as well as the KYN/TRP ratio in HCV patients (n = 16). IFN-alpha administration increased KYN in peripheral blood and KYN, QUIN and KYNA in the CSF after ∼12 weeks compared to control patients. CSF KYN and QUIN correlated with the severity of depressive symptoms and, in addition, plasma KYN and QUIN concentrations correlated with the CSF KYN and QUIN concentrations. Thus, Raison et al. study , though with limited sample size, provides evidence that changes in peripheral KYN metabolism are linked to central nervous system cytokine responses in this specific IFN-alpha-induced depression. Future prospective studies including both peripheral and CSF measures of KP metabolites in mood disorders are required to better define if peripheral and CSF levels are indeed correlated and if they are relevant to the course of illness and treatment.
It is also unknown if any specific kynurenine metabolite could efficiently reflect symptom changes in mood disorders. It has been suggested that downstream metabolites such as KYNA and/or QUIN could possibly allow a more refined understanding of the underlying mechanisms of mood regulation in view of their interaction with inflammatory responses (Myint, 2012) . However, this hypothesis remains to be tested as it is not possible based on the results presented here to comment on whether alterations in kynurenine pathways are a consequence of inflammation or are driven by alterations in cortisol levels possibly modulated by susceptibility to stress (Dantzer et al., 2011) .
In addition to depression, inflammation has been linked to suicidal risk. When plasma KYN and TRP were assayed in patients with MDD with and without a history of suicide attempts, KYN and K/T ratio were significantly higher in MDD patients with suicide attempt while higher KYN, K/T ratio predicted suicide attempt (Sublette et al., 2011) . Cerebrospinal fluid levels of QUIN and KYNA measured in suicide attempters and controls showed that QUIN was significantly elevated in suicidal patients and QUIN correlated with suicide intent scale (Erhardt et al., 2013) . Together these findings suggest that the pharmacologic manipulation of KYN levels might reduce suicide risk.
High KYN levels were associated with increased immune activation in many medical conditions including cancer and depression (Chen and Guillemin, 2009) . Changes in pre and post-treatment KYN levels significantly predicted changes in depression symptoms suggesting that heightened KP activation may contribute to depressive symptoms in patients treated for cancer (Botwinick et al., 2014) . Findings from a pancreatic cancer study yielded similar results, reflecting tumor-induced immunomodulation in the pathophysiology of depression (Botwinick et al., 2014) . However, patients with renal cell carcinoma (Van Gool et al., 2008) , receiving IFN-α showed an increase in K/T ratio during the treatment, but no correlation was observed between psychiatric symptoms and KP metabolites. Thus, KP pathway measures associated with immune activation do not always relate to mood changes.
Limitations of this meta-analysis include the small number of studies included, the nature of case-control studies and absence of randomization, the occurrence of study bias so that studies were generally similar with relatively small sample sizes resulting in relatively low statistical power and the very high level of between studies heterogeneity. There are limitations in the estimation of effect sizes based on the inverse-variance methodology we used in this work especially in relation to the variance introduced by confounders. Hence, we explored all the possible causes of heterogeneity by using meta-regression analyses based on the variables we could consistently extract from the studies. Other approaches such as the Mantel-Haenszel methods offer advantages over the method we used here although constrained in the presence of several confounders and the relatively small sample sizes characterizing the studies included in this review (Tripepi et al., 2010) . Mood disorders are often heterogeneous clinical presentations which limit our ability to generalize the results from this meta-analysis largely based on studies which did not specifically include linear effects. This is particularly relevant in view of the high levels of heterogeneity noted in the analyses, the low power of meta-regressions (Arnone et al., 2012) and the discrepancies in the confounders reported in the original studies. Future work would benefit from focusing on kynurenine changes linked to between-subject heterogeneity to more specifically improve precision and generalizability of the results.
In conclusion, the main finding of our work suggests a reduction in kynurenine metabolites in major depression vs. healthy controls. The direction of the change contravenes the postulated theoretical increase based on findings of low mood in chronic and inflammatory diseases and would require replication and exploration in future studies with particular attention to linear effects. If confirmed, this result suggests possible different etiologies for mood dysregulation. Our findings support a role for kynurenine metabolites variations in the pathogenesis of mood disorders, although it does not allow definitive conclusions due to the complex interaction among epidemiological and clinical factors. This finding is important in guiding further research which would benefit from larger studies preferably comparing kynurenine metabolites in individual experiencing mood disorders with and without inflammatory conditions in comparison with healthy controls. Furthermore, systematic measurements of inflammatory markers, cortisol levels, stress responses and a comprehensive exploration of clinical and epidemiological variables would allow to evaluate the impact of these potential variables on kynurenine metabolites measurements and increase the precision of the findings.
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